Immunic Company Insiders
| IMUX Stock | USD 1.24 0.01 0.81% |
Immunic employs about 77 people. The company is managed by 22 executives with a total tenure of roughly 121 years, averaging almost 5.0 years of service per executive, having 3.5 employees per reported executive. Break down of Immunic's management performance can provide insight into the company performance.
| Andrew Henry President Vice President - Clinical Operations |
| Andrea LoewenRodriguez President Vice President - Regulatory Affairs and Quality Assurance |
Immunic |
Immunic Management Team Effectiveness
The company has return on total asset (ROA) of (0.6813) % which means that it has lost $0.6813 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3128) %, meaning that it created substantial loss on money invested by shareholders. Immunic's management efficiency ratios could be used to measure how well Immunic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.81 in 2024. Return On Capital Employed is likely to rise to -3.19 in 2024. At this time, Immunic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 70.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.7 M in 2024.Common Stock Shares Outstanding is likely to rise to about 46.5 M in 2024, despite the fact that Net Loss is likely to grow to (102.9 M).
Immunic Workforce Comparison
Immunic is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 1,611. Immunic holds roughly 77.0 in number of employees claiming about 5% of equities under Health Care industry.
Immunic Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Immunic insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Toernsen Monika Maria over a month ago Disposition of 30000 shares by Toernsen Monika Maria of Immunic at 4.3 subject to Rule 16b-3 | ||
Daniel Vitt over a month ago Purchase by Daniel Vitt of 14000 shares of Immunic | ||
Daniel Vitt over a month ago Acquisition by Daniel Vitt of 14000 shares of Immunic at 1.3095 subject to Rule 16b-3 | ||
Daniel Vitt over three months ago Acquisition by Daniel Vitt of 1160000 shares of Immunic subject to Rule 16b-3 | ||
Whaley Glenn over six months ago Purchase by Whaley Glenn of 5000 shares of Immunic |
Immunic Notable Stakeholders
An Immunic stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Immunic often face trade-offs trying to please all of them. Immunic's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Immunic's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel Vitt | President CEO, Director | Profile | |
| JD MBA | Executive Chairman | Profile | |
| Andrew Henry | Vice President - Clinical Operations | Profile | |
| Andrea LoewenRodriguez | Vice President - Regulatory Affairs and Quality Assurance | Profile | |
| Richard Murawski | Vice President - Manufacturing | Profile | |
| Tamara Seymour | Interim CFO | Profile | |
| Sanjay Patel | CFO | Profile | |
| Manfred Groppel | Principal Financial Officer, COO | Profile | |
| Jorg Neermann | Director | Profile | |
| Jan Bossche | Director | Profile | |
| Randolph Steer | Independent Director | Profile | |
| Vincent Ossipow | Director | Profile | |
| Phillip Croxford | Independent Director | Profile | |
| Aron Stern | Chief Administrative Officer | Profile | |
| Inderpal Singh | General Counsel | Profile | |
| Jessica Breu | Head Communications | Profile | |
| MBA MD | Ex Chairman | Profile | |
| Andreas Muehler | Chief Medical Officer | Profile | |
| Patrick Walsh | Chief Officer | Profile | |
| Glenn CPA | Chief Officer | Profile | |
| Andreas MD | Chief Officer | Profile | |
| Hella Kohlhof | Chief Scientific Officer | Profile |
About Immunic Management Performance
The success or failure of an entity such as Immunic often depends on how effective the management is. Immunic management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immunic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immunic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.72) | (1.81) | |
| Return On Capital Employed | (3.36) | (3.19) | |
| Return On Assets | (1.72) | (1.64) | |
| Return On Equity | (3.24) | (3.07) |
The data published in Immunic's official financial statements usually reflect Immunic's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Immunic. For example, before you start analyzing numbers published by Immunic accountants, it's critical to develop an understanding of what Immunic's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Immunic's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunic's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Immunic's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immunic. Please utilize our Beneish M Score to check the likelihood of Immunic's management manipulating its earnings.
Immunic Workforce Analysis
Traditionally, organizations such as Immunic use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Immunic within its industry.Immunic Manpower Efficiency
Return on Immunic Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 4.3M | |
| Working Capital Per Employee | 361.1K | |
| Working Capital Per Executive | 1.3M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.